REN-001 is a small molecule commercialized by Reneo Pharmaceuticals, with a leading Phase III program in Mitochondrial Myopathy. According to Globaldata, it is involved in 8 clinical trials, of which 5 were completed, 2 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of REN-001’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for REN-001 is expected to reach an annual total of $181 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

REN-001 Overview

HPP-593 (REN-001) is under development for the treatment of McArdle disease (glycogen storage disorder 5), primary mitochondrial myopathy, MELAS syndrome metabolic syndromes and fatty acid oxidation disorders (FAODs) with confirmed mutations in the Carnitine palmitoyltransferase II deficiency (CPT2), Very long-chain Acyl-CoA dehydrogenase deficiency (VLCAD), Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD) or Trifunctional Protein Deficiency (TFP). It is administered through the oral route. The drug candidate acts by targeting peroxisome proliferator-activated delta receptor (PPAR).

HPP-593 was also under development for the treatment of musculoskeletal disorders, dyslipidemia and type 2 diabetes.

Reneo Pharmaceuticals Overview

Reneo Pharmaceuticals, a biotechnology company that focused on developing treatments for orphan diseases. The company is headquartered in United States.

The operating loss of the company was US$39.8 million in FY2021, compared to an operating loss of US$19.6 million in FY2020. The net loss of the company was US$39.8 million in FY2021, compared to a net loss of US$19.5 million in FY2020.

For a complete picture of REN-001’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.